FRUQUITAS trial: Study design of an ENGIC intergroup randomized phase III of trifluridine/tipiracil +/- fruquintinib in pre-treated metastatic gastro-oesophageal adenocarcinoma
A phase 3 trial is testing whether combining two anti-cancer drugs improves survival in gastroesophageal cancer, a disease with few late-stage options.
The FRUQUITAS trial is a Phase 3 international multicentre RCT testing whether adding fruquintinib (an anti-angiogenic VEGFR inhibitor approved for refractory CRC) to trifluridine/tipiracil can meaningfully improve survival in pre-treated metastatic gastroesophageal cancer. This is a design/protocol paper — no results are available yet — but signals a pipeline advance for a cancer with very limited late-line options.
What the study was
- Study design
- Phase 3 RCT design/protocol paper (ENGIC 06 - PRODIGE 114 - FFCD 2401 trial)
- Population
- Patients with metastatic oesophageal, gastro-oesophageal junction, or gastric adenocarcinoma previously treated with 2-3 lines
- Category
- Drug Development
- Maturity
- Exploratory
- Journal
- Digestive and Liver Disease
Why it surfaced
Phase 3 RCT launch with international intergroup (ENGIC-PRODIGE-FFCD) for a cancer with very limited later-line options. Fruquintinib has demonstrated OS benefit in refractory CRC; rationale for extension to mOGC is plausible. Design paper only — outcome watch required.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.